Insmed price target raised to $67 from $45 at TD Cowen

TD Cowen raised the firm’s price target on Insmed to $67 from $45 and keeps a Buy rating on the shares. The firm said yesterday’s best case scenario ASPEN data drives 80%+ probability of US, EU and Japan approval and they predict clean approval, and model $3.4B in peak sales using a $30K gross price at launch, and 40% peak market share.